CSIMarket Company Name, Ticker, Suppliers, else..
 
Vigil Neuroscience Inc   (NASDAQ: VIGL)
 
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 48
 Employees 16
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -92
 Cash Flow (TTM) (Millions $) 17
 Capital Exp. (TTM) (Millions $) 1

Business Description


Vigil Neuroscience Inc is a biotechnology company that specializes in delivering innovative solutions for brain health. The company's primary focus is on developing advanced diagnostic tools and personalized therapies for neurological disorders. Vigil Neuroscience combines cutting-edge technologies, such as artificial intelligence and machine learning, with extensive knowledge in neuroscience to provide accurate and efficient solutions for brain-related conditions. Their goal is to improve patient outcomes and revolutionize the field of neuroscience by providing transformative treatments for various neurological disorders.


   Company Address: 100 Forge Road, Watertown 2472 MA
   Company Phone Number: 254-4445   Stock Exchange / Ticker: NASDAQ VIGL


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ABOS   -8.93%    
ALEC   -7.18%    
AVXL   -23.53%    
BIIB   -3.39%    
CGTX   -1.27%    
RXRX        10.16% 
• View Complete Report
   



Product Service News

Exploring New Frontiers Vigil Neuroscience Reveals Promising Data on Alzheimers Treatment Amidst Financial Challenges

Published Wed, Apr 2 2025 11:54 AM UTC

In a groundbreaking development for those battling Alzheimer s disease, Vigil Neuroscience has unveiled promising preclinical and clinical data at the prestigious AD/PD 2025 International Conference regarding their innovative small molecule TREM2 agonist, VG-3927. While the company s financial ratios underwent scrutiny due to rising current liabilities, this promising medica...
Clinical Study

Vigil Neuroscience Announces FDA Has Removed Partial Clinical Hold on VG-3927

Published Tue, Sep 17 2024 11:00 AM UTC

Vigil Neuroscience Advances in Neurodegenerative Treatments: FDA Lift on VG-3927 Clinical Hold and Strategic Plans for Iluzanebart In a significant stride towards combating neurodegenerative diseases, Vigil Neuroscience, Inc. (Nasdaq: VIGL), based in Watertown, Massachusetts, has recently announced that the U.S. Food and Drug Administration (FDA) has lifted a partial clini...
Clinical Study

Vigil Neuroscience Unlocks New Insights on ALSP Genetic Mutations and Accelerated Pathways for Innovative Therap...

Published Thu, Aug 1 2024 8:06 PM UTC

Understanding the Landscape of ALSP and Genetic ContributionsOn July 18, 2024, Vigil Neuroscience, Inc. (Nasdaq: VIGL), a promising player in the field of biotechnology, released a significant update pertaining to the genetic foundations of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). This devastating neurodegenerative disease is linked p...
Clinical Study

Vigil Neuroscience Advances Potential Alzheimers Disease Therapy with Positive Phase 1 Clinical Trial Data and Promi...

Published Wed, Jul 24 2024 11:00 AM UTC

Vigil Neuroscience, a pioneering biotechnology company, has recently unveiled encouraging interim data from its ongoing Phase 1 clinical trial evaluating VG-3927 in healthy volunteers. The results underscore the safety, tolerability, pharmacokinetic, and pharmacodynamic properties of VG-3927, supporting its advancement as a potential once-daily oral therapy for Alzheimer s d...
Clinical Study

Advancing the Treatment for Adult-Onset Leukoencephalopathy Vigil Neurosciences Promising Clinical Development Strategy

Published Thu, Jul 18 2024 11:00 AM UTC

In a recent update, Vigil Neuroscience, a pioneering biotechnology company, shared its progress in pursuing an accelerated approval pathway for their therapeutic candidate, Iluzanebart. Specifically designed for the treatment of neurodegenerative diseases, Vigil Neuroscience s innovative strategy was discussed during a Type C Meeting with the U.S. Food and Drug Administratio...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) -
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 1.96
Working Capital Ratio 2.06
Leverage Ratio (MRQ) 1.1
Total Debt to Equity -
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -2.11 $
Revenues (TTM) -
Cash Flow (TTM) 0.35 $
Cash 1.41 $
Book Value 0.87 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) -5,760,312
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.